The Texas Construction News staff writer
DENTON — Swiss pharmaceutical giant Novartis announced it will construct a new 46,000-sq. ft. radioligand therapy manufacturing facility in Denton. Construction is slated to begin this year, with the plant expected to become fully operational by 2028.
The Denton site will serve patients across the southern U.S. and marks the company’s fifth radiopharmaceutical manufacturing facility in its U.S. network. The expansion is part of a larger $23 billion investment strategy by Novartis to boost its manufacturing and research capabilities in the United States over the next five years.
The new plant will generate local jobs in bioengineering, advanced manufacturing, and quality operations to meet the growing demand for next-generation cancer treatments.
